Exhibit 99.1

Corporate Presentation October 2017 *

Safe Harborstatement Forward-Looking StatementsThis presentation contains certain statements that may be deemed to be “forward looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended.Forward looking statements appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned product development and clinical trials; the timing of, and our ability to make, regulatory filings and obtain and maintain regulatory approvals for our product candidates; our intellectual property position; the degree of clinical utility of our products, particularly in specific patient populations; our ability to develop commercial functions; expectations regarding product launch and revenue; our results of operations, cash needs, and spending of the proceeds from this offering; financial condition, liquidity, prospects, growth and strategies; the industry in which we operate; and the trends that may affect the industry or us. As a result, actual results may differ materially from any financial outlooks stated herein. We may, in some cases, use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “targets,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, may differ materially from the forward-looking statements contained in this presentation as a result of a variety of factors including but not limited to those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company’s product candidate and those risks and uncertainties associated with the protection of the Company’s intellectual property rights. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. This document is not intended to be and is not an advertisement for any securities of the Company. For a more complete discussion of the risk factors affecting our business, please refer to our Annual Report on Form 20-F filed on March 9, 2017, with the United States Securities and Exchange Commission which is available on its website at http://www.sec.gov. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. We undertake no obligation to update, amend or clarify such statements to reflect new information or events or circumstances occurring after the date of this presentation or to reflect the occurrence of unanticipated events. This information does not provide an analysis of the Company's financial position and is not a solicitation to purchase or sell securities of the Company. You should independently investigate and fully understand all risks before investing in the Company. 2

Our Mission 3 Provide A New Vision for Colorectal Cancer Prevention That improves the patient experience and maximizes the number screened

C-Scan® system designed to meet CRC screening needs of average-risk populationIngestible capsule-based system with innovative X-ray technology eliminates screening barriers, such as bowel preparation, invasiveness, and sedation AboutCheck-Cap 4 CRCPrevention (pre-cancerous polyp detection) Patient comfort & convenience Visual Examinations Stool/Serum Tests

C-Scan®System C-Scan® Cap -Ingestible scanning capsule 1 C-Scan® Track - Biocompatible unit worn on patient's back for capsule control, tracking and data recording 2 C-Scan® View –application used to process and display structural information 3 Imaging Data + Positioning Data Data upload The Check-Cap System is not available for sale or clinical use in any jurisdiction. 5

Investment Highlights Compelling, large market need for a preparation free alternative that fosters compliance with colorectal cancer screening guidelinesEncouraging C-Scan clinical performance data supporting CE Mark registration filingNear term EU & US market activities: 1H18 EU post market and US pilot initiationsOngoing collaboration with GE Healthcare to develop high-volume, X-ray capsule manufacturing capabilitiesStrong intellectual property protectionFocused management execution on clinical and development programs *

Management 7 Dr. Yoav KimchyFounder & CTO Alex Ovadia COO Dr. Walt Robb(1) Steve Hanley Yuval Yanai Dr. Mary Jo Gorman XQ LinTomer Kariv Clara Ezed Bill Densel CEO Lior Torem CFO BOD (1) Check-Cap US Inc.

Colorectal Cancer a major public health problem 8 137k50k Source: American Cancer Society World Health Organization J Natl Cancer Inst. 2011; 103:1-12 (Mariotto) 135k50k 471k228k 253k139k 113k48k 1.36m694k Annual new cases world-wide -Annual deaths world-wide - Second leading cause of cancer deaths in U.S. Treatment costs projected to be >$17B in 2020

Colorectal Cancer highly preventable 9 Source: Gastro 1997;112:594-692 (Winawer) WEO Atlas, NCI Small Adenomatous Polyp (< 1cm) Colorectal Cancer Pre-cancerous phase, readily detectable by structural examinations of the colon Asymptomatic patient Cancer patient ~10 years

* National Polyp Study:CRC incidence and mortality reduction Source: Winawer et al., NEJM (1993) Zauber et al., NEJM, 2012 number of CRC cases over 7 years

Source: AGA Institute Guidelines for the Early Detection of Colorectal Cancer and Adenomatous Polyps American Cancer Society. Colorectal Cancer Facts & Figures 2017-2019. Atlanta: American Cancer Society; 2017 USPSTF, JAMA. 2016;315(23):2564-2575. doi:10.1001/jama.2016.5989 CRC screening testscancer prevention and cancer detection 11 USPSTF recommendation recognizes that different screening tests may be more or less attractive based on their features Examines entire colonHigh performanceFull bowel preparation, invasive, sedation Visual ExaminationsPrevention & Detection Stool/Serum TestsDetection Will miss most polypsNo bowel preparation, noninvasive, no sedation

Screening in the U.S. and EUa substantially underused strategy Sources: CDC NHIS survey results as published in the CDC’s MMWR between 2006 and 2017 Radiology,. 2017, Ahead of Print, https://doi.org/10.1148/radiol.2017170924 (Smith) goal Screening rates Ages ≥ 50 EU U.S. *

Removal of prepmay increase screening rates 13 86% of respondents would be much or somewhat more likely to undergo screening if laxative prep were to be removed. Source: Mayo Clinic Proc. 2007;82(6):666-671 (Beebe) Laxative preparation Fasting requirements Other reasons Concern over pain Embarrassment Barriers to Colonoscopy screening

Compelling market opportunity 14 $4B annual U. S. market opportunity** Source: * - population between ages 50-84 at average risk, U.S. Census Bureau, Pop. Division, 2014, company estimates ** - For patients screened once every 5 years at average Check-Cap System price of $600 J Clin Gastroenterol 2014 Jan;48(1):52-4 (Chatrath) Potential U.S. screening population of 84M* 575MPopulation age +50 at average risk*

Ultra-low dose X-ray scanning capsule 15 Patented technology detects photons XRF CMT from Compton Back-scattering and X-Ray Fluorescence As the capsule moves naturally, it scans the inner lining of the colon in a 360 degree arc, scanning only when in motion Patients drink a small amount of contrast agent (~1 TBP) with each meal during C-Scan® Cap passage

Patientscontinue their daily routine 16 As C-Scan® Cap travels naturally, it transmits scanning and location data to the C-Scan® Track, mapping the structures of the internal colon. The capsule is excreted naturally and the patient is notified. Capsule route in colon C-Scan® Track Image for illustration only 2-3 days avg. capsule passage

Physician reviewof clinical images 17 Images for illustration only

Intellectual Property robust portfolio 18 Core patents granted in major jurisdictions 30 granted, 2 allowed, and 27 pending worldwide including the U.S. PTO, European Patent Organization, China, Japan, & India covering the core technology: Intra-Lumen Polyp Detection – system and method for an ingestible capsule with an X-ray source not requiring laxative preparationMeasurement of distance between capsule and colon walla method not requiring laxative preparation

Clinical development 19 Source: Gut. 2016 Mar;65(3):371-3 (Gluck) Capsule Motility Evaluation of natural movement of capsule Safety – capsule swallow and passage Normal motility Germany/Israel; 75 patients, 2010 Development, Clinical proof-of-concept Safety – capsule swallow and passage Radiation dosage of 0.06mSv (~chest X-ray 3D colon map and capsule track Polyp identification validated by colonoscopy Clinical Feasibility Israel; 100 patients, 2015-2016 Clinical Performance Evaluation of safety and initial clinical performance Israel; 66 patients, 2017 Safety Clinical Performance(1) (1) In Europe, stool testing is the primary CRC screening test; sensitivity for advanced adenomas ranges from 22% to 40%

* Clinical Performance Study Study parameters Device technology C-Scan system Objectives SafetyClinical performance of preparation-free C-Scan system detection of patients with polyps Subjects 66 patients enrolled 43 with un-resected polyps23 average-risk Site locations Israel (3 sites) Procedures 63 patients completed the C-Scan procedure45 patients included in analysis for polypsAll received stool testing and confirmatory colonoscopy

Clinical Performance StudyResults 52 ± 32 hours average transit time with no change in routine or diet0.05 mSv average radiation dosageNo device related serious adverse eventsMinor anticipated adverse events * Safety √ √ √ √

Clinical Performance StudyResults All analyzed subjects (45) >50% (19) Sensitivity & Specificity 44% * Colon Coverage >20% (35) >70% (12) 55% 78% 100% r2 = 0.98 89% 89% 90% 86% Clinical PerformanceStrong correlation between scanning coverage and polyp detection

Advanced C-Scan VersionShort-term development and clinical objectives Continue clinical & system optimization program to achieve consistently high colon scanning coverageAdvanced C-Scan version underway in clinical evaluationH118: EU post-market study initiationH118: US Pilot study initiationEvaluate marketing and commercialization paths throughout 2018 *

Developmentmilestones * Capital and strategic partner dependent Initiate clinical study for CE Marking - safety and clinical performance CE Mark submission U.S. Pilot Trial H117 H217 U.S. Pivotal Trial initiation - safety and effectiveness OUS Post Market Study EU launch* H118 H218 √ √ * H119

Financial profile 25 Amounts raised: $25.5 million IPO with simultaneous private placement in 2015; $8.7 million total registered direct offerings in 2016-201717.0 million shares outstanding (6/30/17)$31M market cap (9/30/17)Trade on the NASDAQ: CHEKSeries A warrants trade on the NASDAQ: CHEKW$9.2 million of cash, cash equivalents and short-term bank deposits (6/30/17)Analyst coverage: H.C. Wainwright, Maxim Group, Chardan Capital Markets

A New Vision For Colorectal Cancer Prevention *